GKOS GLAUKOS Corp
Price (delayed)
$100.04
Market cap
$5.66B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.77
Enterprise value
$5.59B
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery,
Highlights
The debt has shrunk by 73% YoY and by 34% QoQ
GLAUKOS's equity has surged by 66% YoY and by 15% QoQ
GLAUKOS's net income has decreased by 9% YoY but it has increased by 2.1% QoQ
Key stats
What are the main financial stats of GKOS
Market
Valuations
Earnings
Shares outstanding
56.57M
Market cap
$5.66B
Enterprise value
$5.59B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.19
Price to sales (P/S)
13.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.57
Revenue
$383.48M
Gross profit
$289.45M
Operating income
-$122.37M
Net income
-$146.37M
EBIT
-$135.56M
EBITDA
-$95.64M
Free cash flow
-$67.58M
Per share
Balance sheet
Liquidity
EPS
-$2.77
EPS diluted
-$2.77
Free cash flow per share
-$1.28
Book value per share
$13.91
Revenue per share
$7.27
TBVPS
$12.23
Total assets
$974.76M
Total liabilities
$207.83M
Debt
$103.4M
Equity
$766.93M
Working capital
$374.67M
Debt to equity
0.13
Current ratio
5.99
Quick ratio
5.12
Net debt/EBITDA
0.74
Margins
Efficiency
Dividend
EBITDA margin
-24.9%
Gross margin
75.5%
Net margin
-38.2%
Operating margin
-31.9%
Return on assets
-15.6%
Return on equity
-22.9%
Return on invested capital
-21.6%
Return on capital employed
-15.1%
Return on sales
-35.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GKOS stock price
How has the GLAUKOS stock price performed over time
Intraday
3.04%
1 week
-3%
1 month
-16.65%
1 year
11.8%
YTD
-33.28%
QTD
1.65%
Financial performance
How have GLAUKOS's revenue and profit performed over time
Revenue
$383.48M
Gross profit
$289.45M
Operating income
-$122.37M
Net income
-$146.37M
Gross margin
75.5%
Net margin
-38.2%
The company's operating margin rose by 22% YoY and by 13% QoQ
The revenue has grown by 22% YoY and by 6% from the previous quarter
The company's gross profit rose by 21% YoY and by 4.9% QoQ
The net margin has increased by 11% YoY and by 8% QoQ
Growth
What is GLAUKOS's growth rate over time
Valuation
What is GLAUKOS stock price valuation
P/E
N/A
P/B
7.19
P/S
13.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.57
GLAUKOS's EPS has increased by 6% from the previous quarter
GLAUKOS's equity has surged by 66% YoY and by 15% QoQ
The price to book (P/B) is 32% less than the last 4 quarters average of 10.2 but 13% more than the 5-year quarterly average of 6.2
The P/S is 26% lower than the last 4 quarters average of 18.1 but 11% higher than the 5-year quarterly average of 12.0
The revenue has grown by 22% YoY and by 6% from the previous quarter
Efficiency
How efficient is GLAUKOS business performance
The ROIC is down by 46% year-on-year and by 11% since the previous quarter
The ROE has grown by 18% YoY and by 14% from the previous quarter
The return on assets has declined by 11% year-on-year but it is up by 3.1% since the previous quarter
GLAUKOS's ROS has increased by 7% YoY and by 7% from the previous quarter
Dividends
What is GKOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GKOS.
Financial health
How did GLAUKOS financials performed over time
The company's total liabilities has shrunk by 57% YoY and by 19% QoQ
The quick ratio has grown by 14% from the previous quarter and by 11% YoY
The debt is 87% lower than the equity
The debt to equity has plunged by 84% YoY and by 46% from the previous quarter
The debt has shrunk by 73% YoY and by 34% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.